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ABSTRACT 
Polymeric nanoparticles are of great importance in the treatment of various diseases, due to the flexibility in the modification 
of their structures. Recent advances in the field of nanotechnology facilitate the engineering of multifunctional polymeric 
nanoparticles. All the scientific efforts of the pharmaceuticals companies are mainly focusing on two basic aspects, one is to 
discover new molecules of potential therapeutic interest and second is to develop of a new drug delivery system. In the last 
few decades,  research and development (R&D) scientists has directed their efforts toward formulating novel drug delivery 
systems that includes sustained and controlled release, modified release and targeted drug release dosage forms. Application 
of nanoscience and nanotechnology has opened several new possibilities in development of formulation This review 
compiles the different preparation methods of polymeric nanoparticles and then briefly explained their current potential 
applications. 
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INTRODUCTION 
It has been well documented that drugs predicted from in 
vitro studies, fails to reach at target site in adequate 
quantities in vivo studies1. Correspondingly, a high amount 
of the administered drug is left to act on healthy tissues, 
often to the point of generating dose-limiting side effects2. 
Research related to delivery of drug is clearly moving from 
the micro to nano size range. Therefore, nanotechnology is 
evolving as a potential field in medicine that may provide 
significant therapeutic benefits of existing drugs. The most 
difficult tasks for pharmaceutical researcher is to develop 
an effective nano drug delivery system which is capable of 
carrying drugs, specifically to a desired site of action. 
Attempts have been made to reformulate the existing 
conventional formulations into nano delivery systems for 
better therapeutic use and positive scientific 
breakthroughs. These systems mainly include polymeric 
and solid lipid nanoparticles, liposomes and 
nanoemulsions. The ultimate objective of these 
nanodelivery systems is to markedly improve the efficacy 
and reduce the toxic effects of a drug3. 
Recently, nanoparticles based delivery system has been 
proposed as promising colloidal drug carriers system for 
such purpose4. Nanoparticles (NPs) are a type of colloidal 
drug delivery system which is comprised of particles in size 
range from 10 to 1000 nm. Nanoparticles may or may not 
results size related properties that differ significantly from 
those observed properties in fine or macro particles5. 
Nowadays, nanoparticles are widely used as carrier system 
in variety of applications due to their ability to cross organ 
barriers such as cell membrane and blood brain barrier 
etc6. They are made up from biocompatible polymer and 
lipids that provide sustained and controlled release effect 
by either improved dissolution or diffusion mechanism7,8.  
Now a day’s nanoparticles are considered as very prolific 
device for drug delivery system. Dr. Gregory Gregoriad 
proposed the first liposome’s in 1974 as nanoparticulate 
drug delivery systems which resulted in several 
breakthrough discoveries by multidisciplinary 
approaches3. 
The concepts and approaches established in physics, 
polymer and colloidal chemistry, pharmaceutics, 
biophysics and molecular biology have described 
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nanotechnology as a multidisciplinary field. Currently, 
major research aimed at the development of biocompatible 
nanocarriers for drugs delivery, cell imaging and for other 
biomedical applications9. 
POLYMERIC NANOPARTICLES 
Polymeric nanoparticles (PNs) are submicron-sized 
colloidal particles in which therapeutic agent can be 
encapsulated within their polymeric matrix or adsorbed to 
the surface of nanoparticles. There are two types of 
nanoparticles on basis of formulation method i.e., 
Nanospheres and Nanocapsules10,11 as depicted in Figure 1. 
Nanospheres have a matrix system in which drug is 
uniformly entrapped, dispersed or encapsulated within the 
particles or attached to their surfaces. Nanocapsules are 
the liquid-solid core system in which the drug is restricted 
to a polymer membrane of natural or synthetic polymers12. 
Active moiety is protective by coating and can be used for 
the controlled release and targeting of drugs13,14. 
 
 
Figure 1: Schematic representation of nanospheres and nanocapsules 
Polymeric nanoparticles are prepared from a wide variety 
of natural or synthetic biodegradable (e.g. albumin, 
chitosan, alginate, PLGA) and non-biodegradable polymers 
as describe in Table-1. By the virtue of their nano size, 
polymeric nanoparticles can also be targeted to specific 
cells and locations inside the body15. Depending on the 
nature of polymer properties, they are designed in such a 
way that they can be activated by change in the 
environmental conditions such as physiological pH, 
temperature, or chemical stimuli16. Macrophages are well 
recognized phagocytic cells of the reticuloendothelial 
system  and responsible for the uptake and clearance of 
administered drug loaded nanoparticles. Generally, when 
drug loaded nanoparticles are opsonized, phagocytosis/ 
endocytosis may take place and nanoparticles are degraded 
in a phagolysosome/endolysosome17. However, 
nanoparticles have the capability to escape from the 
endolysomal compartment which may allows the delivery 
of drug to the cytoplasm and finally to the nucleus. Thus, 
NPs are easily taken up by phagocytic cells and that’s 
makes them ideal for intracellular delivery of anti-
retroviral drugs. Other applications of NPs include 
cytoplasmic release of plasmid vectors and therapeutic 
agents15,18,19.
  
Table 1: List of commonly used polymers 
Type of polymers Class of polymers Examples 
Synthetic polymers Polyamide Polyamino acids, Polypeptides 
Polyester Poly(glycolide), Poly(D,L-lactide), Poly(D,L-lactide-co-glycolide), Poly(ε-
caprolactone), Poly(dioxanone) Poly(hydroxybutyrate) 
Polyanhydride Poly[bis(p-carboxyphenoxy) propane-co-sebacic acid], Poly(fatty acid dimmer-
co-sebacic acid), Poly(sebacic-co-recinolic acid) 
Naturally occurring  
polymers 
Polysaccharides Dextran, Chitosan, Alginate, Starch, Hyaluronic acid, Gellan 
Proteins Collagen, Gelatin, Bovine serum albumin (BSA), Human serum albumin (HSA) 
 
BIODEGRADABLE POLYMERS 
Biodegradable polymers are polymer that are comprised of 
monomers linked to each other through a functional group 
and have unstable linkage in backbone that degrades 
within the body by enzymatic or chemical degradation as a 
result of natural biodegradable process15. Also when used 
as drug delivery system it gets eliminated from body and 
need not to remove the delivery system after complete 
release of the active ingredients20. The release of drug from 
biodegradable polymers drug delivery system is generally 
governed by either erosion of surface polymer or swelling 
of polymer and subsequent release of drug or by diffusion 
of physically entrapped drug21. 
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The major biomedical applications of biodegradable 
polymers are 15, 21, 22  
 Constructing depot injections  
 Biodegradable sutures 
 Replacement of bone grafts 
 In tissue generation  
 For protein drug delivery 
 For gene drug delivery for sustain and controlled drug 
delivery systems  
Common characteristics of all biodegradable polymers 
are23  
 Stability and compatibility with the drug molecule 
 Biocompatible and biodegradable in nature 
 Ease of production on a larger scale  
 Suitable  for  sterilization, and  
 Flexibility to prepare delivery system with multiple 
release profiles 
The general advantages of nanoparticles includes24,25  
1. Due to small and narrow particle size distribution of 
nanoparticles, site specific drug delivery can be 
achieved  
2. Provide a sustained and controlled release of active 
drug over a long period 
3. Protection from chemical and enzymatic degradation 
of incorporated drug 
4. Provide a predefine drug release profile 
5. They can be lyophilized and spray dried to resolved 
stability issues  
6. Surface modification can be easily done to achieve 
both active and passive drug targeting 
7. They offer better therapeutic effectiveness response 
per unit dose as compare to conventional dosages 
form 
8. Biodegradability in blood circulation 
9. pH sensitive polymeric nanoparticles can enhanced 
the oral bioavailability of poorly water soluble drugs26  
10. Site specific drug can be achieved by surface targeting 
ligand nanoparticles/magnetic nanoparticles for 
cancer therapy, vaccine and targeted antibodies27  
Limitation of Nanoparticles  
1. Particle aggregation during storage results in increase 
the particle size which is difficult in physical 
handling28   
2. Limited drug loading and burst release29  
3. Overall high production cost and scaling up 
problems30  
4. Intracellular degradation of nanoparticles due to 
phagocytosed by cells they may cause cytotoxic 
effects31  
 
METHODS OF PREPARATION OF POLYMERIC 
NANOPARTICLES  
The selection of materials and method of preparation is 
dependent on following factors:  
 Size of  desired nanoparticles  
 Inherent and physicochemical properties of the drug, 
e.g., aqueous solubility and stability32  
 Surface charge properties and permeability33  
 Degree of biodegradability, biocompatibility, 
Antigenicity and toxicity34   
 Desired drug release rate profile35  
Emulsion and diffusion method 
This is the most widely used method of preparation for 
polymeric nanoparticles. In this method, the encapsulating 
polymer is dissolved in partially water-miscible organic 
phase (such as benzyl alcohol, propylene carbonate, ethyl 
acetate). The organic phase is emulsified by stirring with 
an aqueous solution of a suitable surfactant i.e., anionic 
sodium dodecyl sulfate (SDS), non-ionic polyvinyl alcohol 
(PVA) or cationic didodecyl dimethyl ammonium bromide 
(DMAB). The diffusion of the organic solvent and the 
counter diffusion of water into the emulsion droplets 
induce formation of nanospheres or nanocapsules, 
according to their oil-to-polymer ratio36. 
This technique presents several advantages, such as high 
encapsulation efficiency, no need for homogenization, high 
batch-to-batch reproducibility, ease of scale-up, and 
narrow size distribution. However, disadvantages includes 
that are the high volumes of water is to be eliminated from 
the suspension and less suitable for water-soluble drugs 
due to leakage into the saturated-aqueous external phase 
during emulsification, reducing encapsulation efficiency37. 
While, parameters that influenced the size of nanoparticle 
are: polymer concentration, solvent nature, 
surfactant/polymer molecular mass, viscosity, stirring rate, 
nature of solvent, temperature and rate of water 
addition36. 
Emulsification-solvent evaporation method 
Emulsion evaporation is the most popular and oldest 
method used for preparation of polymeric nanoparticles. 
The method involves two steps; emulsification of an 
organic solvent with a polymer in an aqueous solution of 
surfactant followed by the evaporation of organic phase. 
Which may leads to polymer precipitation and formation of 
nanoparticles. Briefly, the organic phase or aqueous phase 
(internal phase) is poured into an external phase (aqueous 
or organic phase) in which a surfactant is dissolved and is 
emulsified. It was furthers subjected to evaporation of 
organic solvent under vacuum, which leads to polymer 
precipitation and formation of nanoparticle. The 
nanoparticles were collected by centrifugation and washed 
with distilled water to remove surfactant residue or any 
free drug 38.  Most commonly used organic solvents are 
ethyl acetate, chloroform and methylene chloride. Biphasic 
emulsions (o/w or w/o) and multiple emulsions (w/o/w) 
can be used to accommodate the active drug with variable 
properties. The o/w emulsion is used for the entrapment of 
hydrophobic drug, whereas double emulsion (w/o/w) is 
used for the entrapment of hydrophilic drug. This method 
is widely used for the preparation of nanoparticles, 
because it is easy to scale-up, and can be adjusted (by use 
of the double-emulsion method) to encapsulate water-
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soluble drugs39,40. This technique has been successfully 
used for encapsulation of a hydrophobic drug, while in case 
of hydrophilic drug entrapment was less41. Further, 
modification of this method includes automated batch 
scale production and is known as high pressure 
emulsification solvent evaporation process42.  This method 
involves preparation of an emulsion (O/W or W/O) which 
is then subjected to homogenization under high pressure 
followed by high speed stirring to remove any organic 
solvent residue43. The size of nanoparticles can be 
controlled by amount and type of polymer, surfactant, 
viscosity of organic and aqueous phases, temperature and 
rate of stirring44.  Commonly used polymers are Polylactic 
acid, poly (lactic-co-glycolic acid), Ethyl cellulose15, and 
Polycaprolactone45. 
Oil in water emulsion technique (single emulsion) 
This technique is based on the emulsification of an organic 
phase, which contains polymer and drug in an aqueous 
phase, followed by the removal of the organic solvent by 
evaporation method. A number of hydrophilic surfactants 
such as polyvinyl alcohol, or Pluronic F68 are generally 
used in an aqueous phase. For the formation of 
nanoemulsion, size reduction of emulsion droplet is done 
by sonication or microfluidization. The evaporation step is 
required to eliminate the organic solvent present in the 
organic phase. This leads to the precipitation of the 
polymer as nanoparticles with a diameter in the 
nanometric range46.   
There are some considerable variables which effects the 
preparation of nanoparticles that includes molecular mass 
and concentration of polymer, co-polymer ratio and end 
groups, surfactant nature, phase ratio, solvent nature, rate 
of evaporation, drug entrapment, additives and 
sterilization47.  
Double-emulsion (w/o/w) method 
This method is a modification of emulsification solvent 
evaporation method and is useful for encapsulation of 
proteins and hydrophilic drugs. In this method, the 
primary emulsion (w/o) is prepared by a aqueous solution 
containing the hydrophilic drug and polymer in the organic 
phase containing  a suitable surfactant, having low HLB 
value such as Span 80, Pluronic-F68. The primary emulsion 
is produced by strong shear stress and re-emulsified in an 
external aqueous phase of a surfactant for formation of 
water in-oil-in water (w/o/w) emulsion. Further, droplet 
size reduction of emulsion is achieved with the help of 
sonication or homogenization. Finally, organic phase 
residue removed with the help of evaporation under 
vacuum and nanoparticles can be collected by 
centrifugation at high speed48. The major drawback of this 
method is the formulation of large sized nanoparticles and 
the leakage of hydrophilic drugs. Overall production of 
nanoparticles depends upon polymer/surfactant ratio, 
polymer concentration, type and nature of surfactant, 
viscosity, energy input, evaporation and phase ratios49 . 
Solvent displacement/Nanoprecipitation  
This technique was first described by Fessi  et al. 1989 and 
is also called as solvent displacement method50. This 
method is commonly used to incorporate lipophilic drugs 
and involves the precipitation of polymer from an organic 
phase. In this method, drug, polymer and lipophilic 
surfactant (e.g., phospholipids) are added in a semi-polar 
water-miscible solvent (i.e., acetone or ethanol). Under 
magnetic stirring, this solution is added drop wise into an 
aqueous phase solution containing a stabilizer. Rapid 
diffusion of the solvent, facilitate instant formation of 
colloidal nano suspension. Then organic solvent is 
removed under reduced pressure from the suspension51. 
This technique is suitable for lipophilic drugs which allow 
the formation of nanocapsules with high drug loading 
efficiencies. This method is not suitable for water miscible 
solvents, in which the diffusion rate is high to produce 
spontaneous emulsification and may leads to instability 
when added in water. In some cases, the entrapment 
efficiency of drugs can be increase by use of 
acetone/dichloromethane which increases the mean 
particle size. The particles size and drug entrapment 
efficiency depend upon the rates of addition of the organic 
phase into the aqueous phase52. This technique has been 
used for various polymers such as poly(lactic-co-glycolic 
acid), Poly(lactic acid) and Polycaprolactone etc 41,53.   
Dialysis method  
This method is a simple and relatively effective method for 
preparation of polymeric nanoparticles with small and 
narrow size distribution. Briefly, drug and polymer is 
dissolved in an organic solvent and are put in the dialysis 
tube (semi-permeable membranes having a appropriate 
molecular weight cut off) which is kept in a aqueous phase. 
The organic phase diffuses out through the pore of dialysis 
membrane into the aqueous phase which resulted in 
decrease in interfacial tension between two phase. 
Subsequently, displacement of organic solvent results in 
loss of solubility of polymer and may form homogenous 
suspension of nanoparticles54. The mechanism of 
formation of nanoparticles by dialysis method is similar to 
that of nanoprecipitation suggested by the Fessi et al50. 
Emulsion Polymerization Method               
This is in situ polymerization of monomers in an aqueous 
solution containing surfactant which results in formation 
of nanoparticles. Drug is added during polymerization 
process or is adsorbed on nanoparticles after completed 
polymerization.  The nanoparticle can be purified and 
recovered after removal of residues of stabilizers and 
surfactants by centrifugation and reconstituted in an 
isotonic medium55, 56. One another alternative method is 
mini-emulsion polymerization method, in which co-
stabilizer and high-shear energy (sonication, ultrasound, 
etc) is used with mixture of monomer, surfactant and a 
initiator57.  This method has been reported for the 
preparation of nanoparticles from organic and inorganic 
materials and also for hybrid nanoparticles58. 
Salting out method               
This method is reported by Ibrahim et al and 
Bindschaedler et al  and is closely related to solvent-
diffusion method. In this method, the polymer is dissolved 
in water-miscible organic phase, such as acetone or 
tetrahydrofuran. The ideal choice is acetone because of the 
high miscibility with water and can be easily removed. The 
drug and polymer dissolved in organic phase and 
emulsified in an aqueous phase, under high mechanical 
staring. The aqueous phase consisted of emulsifying agent 
with a high concentration of salting out agent. The 
commonly used salting out agent are magnesium chloride, 
calcium chloride, or sucrose. In comparison to the 
emulsion diffusion method, the presence of salts results in 
no diffusion of the solvent59. The rapid addition of water to 
the o/w emulsion under slow stirring reduces the ionic 
strength and which leads to the movement of organic 
solvent to the aqueous phase and resulted in formation of 
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nanospheres. In final step, salting out agent is removed by 
centrifugation60. The salting out method is suitable for heat 
sensitive substances. Important variables to be considered 
includes polymer concentration, nature and concentration 
of surfactant, molecular mass of polymer, stirring speed 
and time, and solvent used and cryoprotectants61,53 . 
Coacervation or Ionic Gelation method 
Nowadays, much attention of research has been focused on 
production of biodegradable nanoparticles using polymers 
such as chitosan, gelatin and sodium alginate having 
features like biocompatibility and low toxicity. Calvo et al 
introduced a method for preparation of hydrophilic 
chitosan nanoparticles by ionic gelation62. In this method, 
one aqueous phases consisted of solution of chitosan 
polymer and a di-block-co-polymer ethylene oxide or 
propylene oxide (PEO-PPO) and the other phase is solution 
of sodium tripolyphosphate. Nano size coacervates are 
formed due to an interaction of cationic group of chitosan 
and anionic tripolyphosphate. Coacervates are produced 
due to electrostatic interaction between both aqueous 
phases whereas conversion of material from liquid to gel 
takes place due to ionic interaction at room temperature. 
Cross-linking agent such as   glutaraldehyde solution (25 
%) can be used for hardening of coacervates63. Desired 
property of the nanoparticles can be achieved by 
concentration of cross linker, temperature, pH, addition 
rate and agitation speed64. 
Spray drying method 
Spray drying has been considered as widely used method 
for the production of nano/micron-sized particles of heat-
sensitive materials. In this method, solution droplet is 
converted into a dry particle by evaporation of the solvent 
in a single-step process. Thermo-labile compounds such as 
proteins and enzymes intended for therapeutic and 
diagnostic purposes have been successfully developed as 
spray-dried product. This method is widely used to 
improve the morphology and particle size of dried powder 
by varying the process variables and the formulation 
factors.  It is also suitable for protein drugs which are 
administered as spray dried powders by pulmonary and 
nasal routes for therapeutic purposes65. It has been 
reported that dried particles of water soluble or water 
insoluble drugs can be prepared by use of various 
polymers which resolved the issue of drug leakage66 and 
thus, the drug amount in particles can be accurately 
determined67. Innovative advancement in spray drying 
technology is impact on development of new spray dryers 
for pharmaceutical industry, which resulted in high 
product yield with nano size range68. 
Supercritical fluid technology method 
In conventional methods, organic solvents used are 
unsuitable for environment as well as to physiological and 
biological systems. Therefore, the supercritical fluid 
technology has been introduced as environmentally safe 
method for preparation of nanoparticles69. Supercritical 
fluids remains as a single phase without impact of pressure 
and having intermediate properties of  a liquid and a gas. 
They are commonly used in the production of inorganic 
and hybrid nanomaterials. Supercritical carbon dioxide 
(SCCO2) is the most extensively used fluid because of its 
safe and non-flammable nature. They are commonly 
employed in supercritical anti-solvent (SAS) and rapid 
expansion of critical solution (RESS) methods. SAS method, 
a solid sample is dissolved in an organic or inorganic liquid 
solvent and which injected into a supercritical fluid under 
the high pressure. Under these conditions, miscibility of 
solid solute is reduced in the supercritical fluid which 
results in the precipitation of the solute and the 
subsequently formation of nanoparticles70.  While in RESS 
method, the solid sample is saturated in a supercritical 
solvent and is passed through a very fine nozzle at high 
speed that resulted in precipitation of the solute due to 
expansion/decompression effect of the system. The overall 
morphology and size distribution of solute particles are 
dependent on expansion conditions. Other factors that 
affect overall production process include nature of solute, 
supercritical solvent, operating pressure and temperature 
conditions. Supercritical fluid technology is appropriate for 
bulk production but costly design of equipment is major 
limitation71 .  
APPLICATIONS OF POLYMERIC NANOPARTICLES 
The extensive advancement in the area of science results in 
innovative ideas which lead to novel drug delivery 
systems. Recently reported outcomes of polymeric 
nanoparticles are summarized in table 2. 
 
Table 2: The research outcomes of polymeric nanoparticle 
S. 
No 
Carrier system Drug 
/Molecule 
Recent applications Year Ref. 
1 PLGA nanomatrix Topotecan and 
Thymoquinone 
Co-delivery of topotecan and thymoquinone from PLGA 
nanomatrix formulated by a modified double emulsion 
solvent evaporation method. In this topotecan (Hydrophilic 
moiety) was solubilized in the inner aqueous phase while 
thymoquinone (lipophilic moiety) was incorporated into the 
organic phase of the double emulsion. Formulated 
nanoparticles were characterized by zeta potential, surface 
morphology, injectability and reconstitution time. The 
optimized formulation had particle size of 240.7± 8.3 nm and 
percent entrapment and loading of 62.6± 2.6 % and 6.52 
± 0.25 respectively for thymoquinone and 42.3 ± 1.2% and 3.6 
± 0.26 for topotecan respectively. DSC and XRD results have 
confirmed the transformation of drug from its crystalline to 
amorphous form when entrapped in the PLGA nanomatrix. 
Drug loaded nanoparticles revealed a sustained release 
pattern of both the drugs with a minimal burst release. The 
short term accelerated stability analysis showed a minimal 
variation in the release pattern. 
2017 72 
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2 Biodegradable 
poly(d,l) lactic acid 
nanoparticles 
Tamoxifen 
citrate 
Biodegradable poly (d,l) lactic acid nanoparticles were 
prepared by modified spontaneous emulsification solvent 
diffusion method. In vitro studies for cytotoxicity revealed 
that MCF-7 and MDA-MB-231 cells lines were more sensitive 
to tamoxifen loaded nanoparticles than tamoxifen citrate 
alone. DNA ladder and the expression of Bax to Bcl-2 ratio 
were higher in tamoxifen loaded nanoparticles than that in 
alone tamoxifen citrate. 
2016 73 
3 Monomethoxy 
polyethylene glycol 
amine-polylactide-
co-glycolide (mPEG-
PLGA) co-polymer 
Gemcitabine Gemcitabine, a nucleoside analog, has a short half-life in 
systemic circulation due to its enzymatic degradation.To 
overcome this problem, monomethoxy polyethylene glycol 
amine-polylactide-co-glycolide (mPEG-PLGA) co-polymer was 
synthesized. Gemcitabine loaded mPEG-PLGA nanoparticles 
(NPs) exhibited sustained drug release profile, compatible 
with blood and enhanced cellular uptake. The cell cytotoxicity 
of mPEG-PLGA NPs were observed in MiaPaCa-2 and MCF-7 
cells. The half-life of gemcitabine loaded nanoparticles was 
remarkably enhanced (19 folds) as compared to pure 
gemcitabine which improved anticancer efficacy in Ehrlich 
ascites bearing Balb-c mice. 
2016 74 
4 Poly(d,l-lactide-co-
glycolide) (PLGA) 
nanoparticles 
nanoprecipitation 
method 
Rapamycin and 
Piperine 
Rapamycin (RPM) with a chemosensitizer (piperine) loaded 
Poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles were 
prepared by nanoprecipitation method for improve oral 
bioavailability and efficacy. Prepared nanoparticles showed 
sustained in vitro drug release and it has been found that the 
uptake of the Rapamycin (P-gp substrate) increased in the 
presence of piperine in an everted gut sac method. 
Pharmacokinetic studies showed improved bioavailability of 
4.8 folds in combination with piperine. An in vitro cell line 
studies indicates better efficacy of rapamycin nanoparticles 
compared to free drug solution which suggests that the use of 
a combination of rapamycin with piperine nanoparticles 
would be a effective approach in the treatment of breast 
cancer. 
2016 75 
5 PLGA nanoparticles, 
Emulsified 
nanoprecipitation 
technique 
Tamoxifen Tamoxifen loaded PLGA nanoparticles (Tmx-PLGA) were 
prepared by emulsified nanoprecipitation technique. Tmx-
PLGA has been evaluated for its better DNA cleavage 
potential, cytotoxicity using Dalton's lymphoma ascite cells 
and MDA-MB231 breast cancer cells. In vitro cytotoxicity 
studies indicate that Tmx-PLGA showed excellent DNA 
cleavage potential as compared to pure Tmx. Fluorescence 
imaging of nuclear fragmentation and condensation exhibiting 
significant increase of apoptosis (70%) in PLGA-Tmx while 
pure drug (58%). Enhanced DNA cleavage potential, nuclear 
fragmentation and condensation in apoptotic cells confirm 
greater bioavailability of PLGA-Tmx as compared to pure Tmx. 
Tamoxifen loaded PLGA nanoparticles may act as a novel 
vehicle for the treatment of cancer. 
2016 76 
6 Biotin-F127-PLA or 
F127-PLA polymeric 
nanoparticles 
Camptothecin Camptothecin incorporated into biotin-F127-PLA or F127-
PLA polymeric nanoparticles (NPs) prepared by a dialysis 
method. Results indicate that the targeted CPT NPs exhibited 
regular spherical shape (mean diameter 180 nm). In vitro 
release exhibited an initial burst (40%) within 12 h, followed 
by a slow release of camptothecin. The in vitro antitumor 
effect of the Camptothecin -loaded nanoparticles was 
determined against H22 cells using an MTT assay which 
exerted significant antitumor effects as compared to free 
Camptothecin. The targeted Camptothecin NPs showed 
increased in vivo tumor inhibition. 
2016 77 
7 PLGA/Solutol HS15 
nanoparticles 
Docetaxel Docetaxel loaded PLGA/Solutol HS15 nanoparticles (NPs) 
were fabricated by a modified emulsification solvent 
evaporation method. in vitro release studies, indicates that 
emulsifying property of Solutol HS15 seemed to contribute to 
the enhanced drug release of Docetaxel from NPs at 
physiological pH. These NP can be a promising local 
anticancer drug delivery system for cancer therapy.  
2016 78 
8 biotinylated 
chitosan-poly(d,l-
Epirubicin Surface modification of poly(d,l-lactide-co-glycolide) 
nanoparticles with biotinylated chitosan of Epirubicin loaded 
2016 79 
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lactide-co-glycolide) 
nanoparticles  
were prepared for tumor targeted and prolonged delivery 
system for Epirubicin (EPB). The results revealed 
encapsulation efficiency (84.1 ± 3.4%), spherical shaped, 
higher positive zeta potential compared to the unmodfied 
EPB-loaded PLGA NPs. The in vitro drug release studies 
showed constant drug release kinetics during the first 48 h 
and the drug burst release significantly decreased in 
comparison to the unmodified PLGA NPs. The results of MTS 
assays and the flow cytometry and the confocal microscope 
showed that Bio-CS-PLGA NPs markedly increased the 
cytotoxicity and extent of cellular uptake of EPB. In MCF-7 
tumor-bearing nude mice, EPB-loaded biotinylated chitosan -
PLGA NPs were efficiently accumulated in the tumors which 
displayed greater potential for application as the carriers of 
anti-cancer drugs.  
9 Eudragit E 100 
nanoparticles, 
Emulsification 
diffusion evaporation 
method 
Curcumin Curcumin loaded Eudragit E 100 nanoparticles were prepared 
by emulsification diffusion evaporation method to enhance 
the bioavailability and anti-cancer efficacy. The in vitro 
cytotoxicity sulphorhodamine B assay, showed 19-fold 
reduction in IC50 when treated with curcumin  loaded 
nanoparticles  as compared to pure curcumin, 
Pharmacokinetic studies revealed  ~91-fold increase in Cmax 
and ~95-fold increase in AUC0. The in vivo anti-cancer activity  
showed a significant increase in efficacy compared with pure 
curcumin, as observed by tumor volume, body weight and 
survival rate. Its offer a great potential to improve 
bioavailability and efficacy of hydrophobic chemotherapeutic 
anticancer drug.  
2016 80 
10 Lipid polymer hybrid 
nanoparticles 
Docetaxel Docetaxel (DTX) lipid polymer hybrid nanoparticles consist of 
a pH-responsive PEG layer that gets detached prior to its 
cellular uptake. Docetaxel was added into the lipid core of the 
nanoparticles, which was then protected with the pH-
responsive block co-polymer polyethylene glycol-b-
polyaspartic acid using a modified-emulsion method. Drug 
release from docetaxel loaded nanoparticles was pH-sensitive, 
which is helpful in tumor targeting. The negative surface 
charge and PEG shell of vehicle enhanced the blood 
circulation time and improved physiological activity of 
docetaxel loaded nanoparticles as compared to free docetaxel. 
In vivo anticancer effect of Docetaxel lipid polymer hybrid 
nanoparticles was further confirmed by the elevated levels of 
poly ADP ribose polymerase and caspase-3 found in the 
tumors after treatment. Thus, the results indicate that 
Docetaxel lipid polymer hybrid nanoparticles system could be 
an effective new treatment for cancer. 
2015 81 
11 methoxy 
poly(ethylene 
glycol)-poly(lactide) 
polymeric 
nanoparticles 
5-Flurouracil  5-FU loaded methoxy poly (ethylene glycol)-poly (lactide) 
based polymeric nanoparticles were prepared by 
nanoprecipitation method in order to increase the efficacy 
against breast cancer. The prepared nanoparticles were 
evaluated by DLS, TEM, in vitro release kinetics, and in vivo 
parameters. The average particle diameter of 5-FU loaded NP 
was ~110 nm. The NPs exhibited a pH-dependent drug 
release pattern and in vitro cytotoxicity assay showed the 
enhanced cytotoxic effect of drug loaded NPs in comparison to 
free drug. Flow cytometer analysis showed that nanoparticle 
system remarkably arrested the G2/M phase of cell cycle with 
significant amount of apoptosis cells in late and early phase. 
Nanoparticle formulation significantly decreased the tumor 
burden of mice with minimal signs of adverse effect. The 
favorable results obtained from this study makes 5-FU loaded 
methoxy poly(ethylene glycol)-poly(lactide) based polymeric 
nanoparticles one of the possible alternative for the successful 
breast cancer therapy. 
2015 82 
12 poly(lactic-co-
glycolic acid)coating 
on Mg-Al layered 
double hydroxide 
(LDH) nanoparticles 
Methotrexate It has been reported that development of methotrexate loaded 
poly(lactic-co-glycolic acid)coating on Mg-Al layered double 
hydroxide (LDH) nanoparticles prepared by  double and 
single emulsion-solvent evaporation technique. The optimized 
nanoparticles were assessed for in vitro drug release kinetics, 
2015 83 
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time and dose dependent in vitro cell viability assay and in 
vitro MTX uptake study using MG-63 cell line (human 
osteosarcoma). The results of in vivo pharmacokinetic study 
revealed the much higher therapeutic efficacy of the 
optimized PLGA-LDH-MTX and PLGA-MTX nanoparticles in 
terms of the enhanced half life of the MTX and the slow 
clearance rate compared to those of the pure drug.  
13 pectin nanoparticles 5-Fluorouracil 5-FU-loaded pectin nanoparticles (5-FU-NPs) with an average 
diameter of 300 nm are found to posses greater potency in 
killing cancer cells in HepG2 and A549 cell lines compared to 
that of the free drug. Pharmacokinetics study using Sprague 
Dawley rats further confirmed that the 5-FU-loaded 
nanoparticles showed a longer half life in the circulation fluids 
than the free 5-fluorouracil.  
2014 84 
14 poly(d, l-lactide-co-
glycolide) 
nanoparticles 
Carboplatin Carboplatin-loaded poly(d, l-lactide-co-glycolide) 
nanoparticles were formulated by double emulsion-solvent 
evaporation technique. Nanoparticles showed sustained 
release of carboplatin over 7 days. Cellular uptake of 
carboplatin encapsulated in nanoparticles was several fold 
higher than that with free carboplatin in A549 (lung) and 
MA148 (ovarian) tumor cells and reduction in the IC50 of 
carboplatin in several cell lines. Confocal microscopic analysis 
revealed the existence of carboplatin nanoparticles in 
lysosomes, cytoplasm, and the nucleus of cells. These results 
revealed the enhanced Cellular uptake, therapeutic efficacy 
and reduced toxicity may be achieved with this approach.  
2014 85 
 
CONCLUSION 
The advantageous effects of polymeric nanoparticles 
depend on their physicochemical properties such as size, 
shape, and surface properties. The potential advantages of 
nanoparticles are improved bioavailability, increased 
aqueous solubility, increased bio-distribution of drug in the 
body and targeting the drug to specific location within the 
body. Emerging technologies and method of preparation 
play a critical for development of safe and effective drug 
delivery system. Polymeric nanoparticles based drug 
delivery system has a promising future in the areas of 
diagnosis, imaging, and therapeutics 
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